Company Profile

Aceragen Inc (AKA: Idera Pharmaceuticals Inc~Hybridon Inc)
Profile last edited on: 6/6/2024      CAGE: -----      UEI: ----------

Business Identifier: Oligonucleotide therapies for cancer and rare diseases
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

15 Tw Alexander Drive
Durham, NC 27709
   (617) 679-5500
Location: Multiple
Congr. District: 04
County: Durham

Public Profile

Originally dba Hybridon Inc., and Idera Pharmaceuticals, Inc., Aceragen is a rare disease biopharmaceutical company. Firm address rare, orphan diseases that typically have no available treatment, and strive to develop novel therapies which can have a positive impact on the lives of patients and families. As such, the needs of the patients who suffer from neglected rare diseases drive our mission first and foremost. Aceragen's goal is to provide rare disease patients with compelling new therapeutic options that will allow them to lead the fullest lives possible. Such diseases have been frequently overlooked for drug development and remain “orphan” due to the assumption that they have a small individual footprint. Company aims to change this outlook, engaging in community awareness, regulatory outreach, and most importantly, delivering novel treatments. By focusing on rare and orphan diseases, Aceragen hope to bring a much-needed spotlight to the area by leveraging our collective conviction that these efforts will change the world for the better.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
1998 1 NIH $79,635
Project Title: Antisense Oligonucleotides Aganist Malaria In Vivo
1993 1 NIH $50,000
Project Title: Antisense inhib of vascular endothelial growth factors
1993 1 NIH $50,000
Project Title: Regulation of multidrug resistance with antisense DNA
1993 1 NIH $50,000
Project Title: Antisense DNA inhibition of repsiratory syncytial virus

Key People / Management

  Vincent J Milano -- President, CEO & Director

  Sudhir Agrawal -- Former President and CEO

  Robert Kilkuskie

  Gregory S Robison

  Eric H VonHofe

  Paul C Zamecnik